Decreased prostaglandin synthetase activity during kidney regeneration after folic acid or 2,4,5-triamino-6-styrylpyrimidine application.
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D005492:Folic Acid / Q000494:pharmacology*; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D007679:Kidney Medulla / Q000187:drug effects / Q000378:metabolism; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009929:Organ Size / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011453:Prostaglandins / Q000096:biosynthesis; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D012038:Regeneration / Q000187:drug effects*; D013343:Styrenes / Q000494:pharmacology*
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D011743:Pyrimidines; D013343:Styrenes; C015549:2,4,5-triamino-6-styrylpyrimidine; D005492:Folic Acid; D006899:Mixed Function Oxygenases; D011451:Prostaglandin-Endoperoxide Synthases